At the recent Alzheimer's Association International Conference (AAIC 2026), Biogen presented the results of a mid-stage trial for its experimental tau-targeting drug. The trial, which involved 250 patients with Alzheimer's disease, aimed to assess the safety and efficacy of the treatment. According to Biogen, the results were mixed, with some patients experiencing significant improvements in cognitive function, while others showed little to no change. Despite the mixed results, the company's shares have reacted favourably to the news, rising by 5% in response to the announcement.
Biogen's drug is designed to target the tau protein, which is believed to play a key role in the development of Alzheimer's disease. Previous studies have suggested that targeting tau may be a promising approach to treating the condition. The company's shares have been volatile in recent months, with investors closely watching the progress of its Alzheimer's pipeline.
While the trial results were mixed, they provided valuable insights into the effectiveness of the drug in different patient populations. Biogen plans to continue testing the treatment in larger, more definitive trials. If successful, the drug could potentially offer a new treatment option for patients with Alzheimer's disease.
The Alzheimer's Society has welcomed the news, stating that it is 'encouraged' by the progress being made in the development of new treatments. However, the charity also cautioned that more research is needed to fully understand the potential of the drug.
According to the Alzheimer's Society, there are currently over 900,000 people living with dementia in the UK, with numbers expected to rise to over 1 million by 2026. The charity estimates that a new treatment for Alzheimer's could save the NHS £2.5 billion per year.